| Autor: |
Mark J. Jameson, Daniel Gioeli, Emanuel F. Petricoin, Julie Wulfkuhle, Linnea E. Taniguchi, Abel P. David, Rolando E. Mendez, Adam Spencer, Christine E. Lehman, Michael I. Dougherty |
| Rok vydání: |
2023 |
| Popis: |
Supplemental Figure 2: Knockdown of PRAS40 is insufficient to alter downstream signaling and therefore sensitivity to gefitinib or desIGF1. OSC19 cells were transfected with siRNA specific to PRAS40 (siRNA #1 and siRNA #2) or a scramble siRNA followed by treatment with desIGF1, gefitinib or the combination of both. (A) Immunoblot representation and quantification of PRAS40, phospho-S6 and S6 48 hours after siRNA transfection. (B) OSC19 cell viability as measured by CyQUANT 72 h following transfection and drug treatment. (C) Relative expression of TRAIL (left panel) and PINK (right panel) 48 hours after transfection and 6 hours post drug treatment as quantified by qPCR. Data represents results from at least 3 biological replicates. Asterisks represent significant changes with p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
